title: A randomised double blind trial versus placebo does not confirm the benefit of alpha-interferon in polyneuropathy associated with monoclonal IgM.
authors.forename: X
authors.initials: X
authors.lastname: Mariette
authors.forename: J C
authors.initials: JC
authors.lastname: Brouet
authors.forename: S
authors.initials: S
authors.lastname: Chevret
authors.forename: J M
authors.initials: JM
authors.lastname: Leger
authors.forename: P
authors.initials: P
authors.lastname: Clavelou
authors.forename: J
authors.initials: J
authors.lastname: Pouget
authors.forename: J M
authors.initials: JM
authors.lastname: Vallat
authors.forename: C
authors.initials: C
authors.lastname: Vial
mesh_terms: D000368:Aged; D001323:Autoantibodies / Q000097:blood*; D017322:Clinical Trials, Phase II as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood*; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018992:Myelin-Associated Glycoprotein / Q000276:immunology; D010523:Peripheral Nervous System Diseases / Q000188:drug therapy* / Q000276:immunology*; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D001323:Autoantibodies; D007075:Immunoglobulin M; D016898:Interferon-alpha; D018992:Myelin-Associated Glycoprotein